Castle Biosciences price target raised to $45 from $40 at BTIG
BTIG raised the firm’s price target on Castle Biosciences (CSTL) to $45 from $40 and keeps a Buy rating on the shares. The company ...
Tactile Systems cut to Neutral at BTIG after Q3 revenue miss
Tactile Systems (TCMD) stock was downgraded by BTIG to neutral as its Q3 revenue misses expectations. Read more here.
BTIG Research Upgrades Wingstop (NASDAQ:WING) to Buy
BTIG Research upgraded shares of Wingstop (NASDAQ:WING – Free Report) from a neutral rating to a buy rating in a research ...
Business Insider1d
BTIG Sticks to Its Buy Rating for GE Healthcare Technologies Inc (GEHC)
BTIG analyst Ryan Zimmerman maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) yesterday and set a price target of $99.00. The company’s shares closed yesterday at ...
bovnews11h
Synchrony Financial (SYF) Stock: Greater Than Its Current Valuation?
On Monday, Synchrony Financial (SYF) stock saw a decline, ending the day at $55.06 which represents a decrease of $-0.19 or -0.34% from the prior close of $55.25. The stock opened at $54.96 and ...
Yahoo Finance5d
Wingstop lifted to Buy at BTIG, 'multiple levers remain'
Investing.com -- BTIG upgraded Wingstop (NASDAQ:WING) to Buy with a price target of $370 on Thursday, citing opportunities for long-term growth despite recent concerns around the company's fourth ...
Viking slips as manufacturing concerns cloud promising oral obesity drug data
Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...
Nasdaq6d
Wingstop upgraded to Buy from Neutral at BTIG
BTIG upgraded Wingstop (WING) to Buy from Neutral with a $370 price target The analyst cites the post-earnings selloff in the shares for the upgrade. The decline below $300 represents an ...
D.R. Horton price target lowered to $186 from $190 at BTIG
BTIG lowered the firm’s price target on D.R. Horton (DHI) to $186 from $190 and keeps a Buy rating on the shares. The firm ...
Last week’s selloff was the “appetizer” and BTIG says this week may be the “main course”
Wall Street anticipates further downside market pressure as BTIG's Jonathan Krinsky warns of potential stock market corrections.
Nasdaq4d
Iqvia price target lowered to $260 from $290 at BTIG
BTIG lowered the firm’s price target on Iqvia (IQV) to $260 from $290 and keeps a Buy rating on the shares. The company’s total revenue, adjusted EBITDA, and adjusted EPS all exceeded ...